Condition: Solid Tumors Harboring MET Amplification · Sponsor: AbbVie
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of locally advanced or metastatic solid tumors that harbor MET amplification. This study will have 1 arm where participants will receive telisotuzumab adizutecan. Approximately 100 participants 12 years of age or older. with solid tumors harboring MET amplification will be enrolled in the study in up to 50 sites around the world. Participants will receive intravenous (IV) telisotuzumab adizutecan, as part of the 61.5 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| Beverly Hills Cancer Center /ID# 275465 | Beverly Hills, California, United States | Recruiting |
| City of Hope National Medical Center /ID# 275613 | Duarte, California, United States | Recruiting |
| Valkyrie Clinical Trials /ID# 275547 | Los Angeles, California, United States | Recruiting |
| Yale University School of Medicine /ID# 275978 | New Haven, Connecticut, United States | Recruiting |
| Florida Cancer Specialists - North /ID# 277137 | St. Petersburg, Florida, United States | Recruiting |
| Northwestern University Feinberg School of Medicine /ID# 276436 | Chicago, Illinois, United States | Recruiting |
| University of Chicago Medical Center /ID# 275342 | Chicago, Illinois, United States | Recruiting |
| START Midwest /ID# 276603 | Grand Rapids, Michigan, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 275999 | New York, New York, United States | Recruiting |
| Duke Cancer Institute /ID# 275604 | Durham, North Carolina, United States | Recruiting |
| SCRI Oncology Partners /ID# 275686 | Nashville, Tennessee, United States | Recruiting |
| Dell Seton Medical Center /ID# 276474 | Austin, Texas, United States | Recruiting |
+ 25 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07196644